Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
2(13%)
Results Posted
50%(5 trials)
Terminated
2(13%)

Phase Distribution

Ph early_phase_1
2
13%
Ph phase_4
3
19%
Ph phase_1
6
38%
Ph not_applicable
5
31%

Phase Distribution

8

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
2(12.5%)
Phase 1Safety & dosage
6(37.5%)
Phase 4Post-market surveillance
3(18.8%)
N/ANon-phased studies
5(31.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(10)
Terminated(3)
Other(1)

Detailed Status

Completed10
Recruiting2
Terminated2
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (12.5%)
Phase 16 (37.5%)
Phase 43 (18.8%)
N/A5 (31.3%)

Trials by Status

recruiting213%
withdrawn16%
terminated213%
completed1063%
unknown16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT04751331Phase 1

Neural Response to Inflammatory Challenge in Major Depressive Disorder

Recruiting
NCT06624436Phase 4

Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Recruiting
NCT03953196Early Phase 1

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Completed
NCT04057807Early Phase 1

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

Completed
NCT03271814Phase 1

Brain Biomarker on Inflammation Response

Withdrawn
NCT05570643Not Applicable

The Effects of Human Endotoxemia on Functional Capacity of Hematopoietic Stem and Progenitor Cells

Completed
NCT03426995Phase 1

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

Terminated
NCT02875028Phase 4

Vorapaxar in the Human Endotoxemia Model

Completed
NCT01587807Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057

Completed
NCT02642237Not Applicable

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response

Completed
NCT01965600Phase 1

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

Terminated
NCT02246543Not Applicable

Whey Protein Study - Identification of Sustainable Satiety

Completed
NCT02157155Not Applicable

A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis

Completed
NCT01091571Phase 4

The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia

Completed
NCT01081392Not Applicable

Inflammatory Markers in Sputum After LPS Inhalation

Unknown
NCT00284869Phase 1

Ethnic Differences in the Inflammatory Response in Systemic Inflammation

Completed

All 16 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
16